P/E ratio for MacroGenics (MGNX)
P/E ratio as of June 2025 (TTM): -0.8581
According to MacroGenics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.858108. At the end of 2024 the company had a P/E ratio of -3.02.
P/E ratio history for MacroGenics from 2013 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -3.02 | -95.29% |
| 2023 | -64.1 | 1763.79% |
| 2022 | -3.44 | -28.77% |
| 2021 | -4.83 | -49.83% |
| 2020 | -9.63 | 190.36% |
| 2019 | -3.32 | 9.76% |
| 2018 | -3.02 | -91.41% |
| 2017 | -35.2 | 190.91% |
| 2016 | -12.1 | -75.52% |
| 2015 | -49.4 | 102.75% |
| 2014 | -24.4 | -96.52% |
| 2013 | -701 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | -2.72 | 216.80% | 🇺🇸 USA |
 Pfizer PFE | 17.4 | -2,132.24% | 🇺🇸 USA |
 Merck MRK | 11.4 | -1,431.88% | 🇺🇸 USA |
 Gilead Sciences GILD | 22.5 | -2,723.75% | 🇺🇸 USA |
 Amgen AMGN | 25.3 | -3,043.55% | 🇺🇸 USA |
 Eli Lilly LLY | 64.4 | -7,599.16% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 17.4 | -2,128.50% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.